Projects funded by the NCN


Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Search results

15 projects found matching your search criteria :

  1. Simultaneous stimulation of muscarinic M4 receptor and selected receptors involved in the regulation of glutamate releas...

    Call: OPUS 9 , Panel: NZ7

    Principal investigator: dr hab. Joanna Wierońska

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  2. Synthesis and pharmacological evaluation of novel benzizoxazolepropylpyrolidine derivatives as multifunctional ligands w...

    Call: SONATA 8 , Panel: NZ7

    Principal investigator: dr Monika Marcinkowska

    Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Farmaceutyczny

  3. Antidepressats as substances that increase the activity of risperidone, an atypical antipsychotic drug in animal models

    Call: PRELUDIUM 5 , Panel: NZ7

    Principal investigator: Katarzyna Kamińska

    Instytut Farmakologii PAN

  4. Interaction of dopamine receptors with G proteins – structural and kinetic aspects

    Call: OPUS 1 , Panel: NZ1

    Principal investigator: dr Agnieszka Polit

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  5. The effect of imipramine and risperidone on regulation of the chronic mild stress-induced anhedonia and memory impairmen...

    Call: OPUS 5 , Panel: NZ7

    Principal investigator: dr hab. Mariusz Papp

    Instytut Farmakologii PAN

  6. Synthesis and pharmacological properties of mono- di- and triheterocyclic azole derivatives as a hybrid receptor and PDE...

    Call: OPUS 4 , Panel: NZ7

    Principal investigator: prof. Maciej Pawłowski

    Uniwersytet Jagielloński - Collegium Medicum, Collegium Medicum, Wydział Farmaceutyczny

  7. The group III metabotropic glutamate receptors as a target for future antypsychotic drugs

    Call: MAESTRO 3 , Panel: NZ7

    Principal investigator: prof. Andrzej Pilc

    Instytut Farmakologii PAN

  8. The effect of prolonged treatment with the new antipsychotics brexpiprazole and lumateperone on human liver function usi...

    Call: OPUS 26 , Panel: NZ4

    Principal investigator: dr Przemysław Danek

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  9. Molecular profiling of novel antipsychotic drug candidates

    Call: OPUS 20 , Panel: NZ7

    Principal investigator: dr hab. Jan Rodriguez Parkitna

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  10. Novel multi-target ligands of aminergic GPCRs as pharmacological tools to study the pathomechanism of schzophrenia

    Call: OPUS 14 , Panel: NZ7

    Principal investigator: dr hab. Agnieszka Kaczor

    Uniwersytet Medyczny w Lublinie, Wydział Farmaceutyczny

  11. Atypical antipsychotic drugs effects on pro-and antioxidative processes, and apoptosis - a study in blood cells, plasma,...

    Call: OPUS 1 , Panel: NZ4

    Principal investigator: dr hab. Anna Dietrich-Muszalska

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

  12. Comparative effects of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) and olanzapine on the cognitive dysfunction meas...

    Call: OPUS 13 , Panel: NZ7

    Principal investigator: dr hab. Agnieszka Wąsik

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  13. Characterization of clozapine and risperidone mechnism of action at the cell nucleus level

    Call: OPUS 13 , Panel: NZ4

    Principal investigator: dr hab. Sylwia Kędracka-Krok

    Uniwersytet Jagielloński, Wydział Biochemii, Biofizyki i Biotechnologii

  14. The role of the neuron-microglia CX3CL1-CX3CR1 and CD200-CD200R protein systems in molecular mechanisms of antipsychotic...

    Call: OPUS 10 , Panel: NZ7

    Principal investigator: prof. Agnieszka Basta-Kaim

    Instytut Farmakologii im. Jerzego Maja Polskiej Akademii Nauk

  15. 5-HT6 receptor ligands as addition to antipsychotic therapy in schizophrenia - an impact on body weight, metabolic param...

    Call: OPUS 10 , Panel: NZ7

    Principal investigator: prof. Anna Wesołowska

    Uniwersytet Jagielloński Collegium Medicum, Collegium Medicum, Wydział Farmaceutyczny